-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written by | Edited by Wang Cong | Typeset by Wang Duoyu | Shui Chengwen Pancreatic Cancer is a malignant gastrointestinal cancer with a high degree of malignancy, which is difficult to diagnose and treat
.
In recent years, the incidence and mortality of pancreatic cancer have increased significantly.
The early diagnosis rate of pancreatic cancer is not high, and it is often found at an advanced stage.
At this time, the cancer cells have spread.
Although some chemotherapy drugs are effective, they usually develop drug resistance.
Cancer immunotherapy also struggles to work
.
The 5-year survival rate of pancreatic cancer is less than 10%, and it is the malignant tumor with the worst prognosis, so it is also called "the king of cancer"
.
According to the latest WHO data, pancreatic cancer is the seventh most common cancer in China in 2020 (an estimated 120,000 new cancers in 2020) and the sixth most fatal cancer (an estimated 120,000 deaths in 2020)
.
Recently, City of Hope National Medical Center, the world's top cancer research and treatment institution, and CytoImmune Therapeutics, a cell therapy innovation company, jointly published a paper entitled: Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell in Gastroenterology, the top journal of gastroenterology.
Preclinical research paper on therapy to treat pancreatic cancer
.
The umbilical cord blood-derived engineered CAR-NK cell therapy (PSCA-CAR_s15-NK) developed in this study has a significant effect in a mouse model of human metastatic pancreatic cancer, lasting more than 90 days in the mouse, significantly extending its lifespan, and showed no treatment-related toxicity, this preclinical study supports the therapy's entry into human clinical trials this year
.
About 60%-80% of pancreatic cancers highly express prostate stem cell antigen (PSCA), so the research team chose to construct PSCA-CAR, in addition to knocking in secreted IL-15 to maintain the survival of NK cells
.
The CAR-NK cells used in the study underwent a freezing and thawing process, indicating that this allogeneic CAR-NK therapy can be used as a novel "off-the-shelf" cell therapy
.
The research team believes that this CAR-NK therapy is promising for the treatment of pancreatic cancer for two reasons: First, the therapy is based on a precision medicine approach, targeting a specific target for pancreatic cancer patients - PSCA; this is an immunotherapy, Using engineered human natural killer cells, engineered to specifically attack cancer cells
.
In addition, solid tumors such as pancreatic cancer, gastric cancer and prostate cancer also highly express prostate stem cell antigen (PSCA).
Therefore, this CAR-NK cell therapy is also promising for gastric and prostate cancer
.
Michael Caligiuri (left), Yu jianhua (right) The research was led by Prof.
Yu jianhua and Prof.
Michael Caligiuri.
Prof.
Yu is the founding director of the NK Cell Biology Research Program at the T-Cell Immunotherapy Center of the City of Hope National Medical Center.
Many important breakthroughs have been made in the fields of biology, CAR-NK, CAR-T, oncolytic virus, and double antibody
.
Professor Michael Caligiuri is the Dean of the City of Hope National Medical Center, the former President of the American Cancer Society (AACR), and a world-renowned medical scientist.
He was elected to the National Academy of Medicine for his breakthrough discoveries in the field of NK cells.
- NK cell therapy has paved the way into the clinic, with more than 1,000 cancer patients currently receiving NK cell therapy designed or co-designed by Michael Caligiuri
.
CytoImmune Therapeutics is developing an NK cell therapy platform designed to overcome the limitations of current engineered NK cell therapies
.
Obtain a large number of NK cells from umbilical cord blood, then add CAR to efficiently identify specific tumor targets, and increase the persistence of CAR-NK cells in vivo by knocking in secreted IL-15
.
More importantly, this engineered CAR-NK can be frozen, stored, and transported without affecting the therapeutic effect, thus enabling "off-the-shelf" cell therapy, which greatly reduces the cost of cell therapy
.
CytoImmune Therapeutics' technology comes from Professor Michael Caligiuri and Professor Yu jianhua, who are also co-founders of the company
.
Reference: https:// https:// /20220118005366/en/ "Bioworld" recently launched the "NK cell therapy" column, which interprets and introduces the latest research progress and reviews of NK cell therapy every week, as well as reports and interviews of related startups
.
We have also established a professional exchange group for NK cell therapy, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.
Open reprint welcome to forward to Moments and WeChat groups
.
In recent years, the incidence and mortality of pancreatic cancer have increased significantly.
The early diagnosis rate of pancreatic cancer is not high, and it is often found at an advanced stage.
At this time, the cancer cells have spread.
Although some chemotherapy drugs are effective, they usually develop drug resistance.
Cancer immunotherapy also struggles to work
.
The 5-year survival rate of pancreatic cancer is less than 10%, and it is the malignant tumor with the worst prognosis, so it is also called "the king of cancer"
.
According to the latest WHO data, pancreatic cancer is the seventh most common cancer in China in 2020 (an estimated 120,000 new cancers in 2020) and the sixth most fatal cancer (an estimated 120,000 deaths in 2020)
.
Recently, City of Hope National Medical Center, the world's top cancer research and treatment institution, and CytoImmune Therapeutics, a cell therapy innovation company, jointly published a paper entitled: Off-the-shelf PSCA-directed chimeric antigen receptor natural killer cell in Gastroenterology, the top journal of gastroenterology.
Preclinical research paper on therapy to treat pancreatic cancer
.
The umbilical cord blood-derived engineered CAR-NK cell therapy (PSCA-CAR_s15-NK) developed in this study has a significant effect in a mouse model of human metastatic pancreatic cancer, lasting more than 90 days in the mouse, significantly extending its lifespan, and showed no treatment-related toxicity, this preclinical study supports the therapy's entry into human clinical trials this year
.
About 60%-80% of pancreatic cancers highly express prostate stem cell antigen (PSCA), so the research team chose to construct PSCA-CAR, in addition to knocking in secreted IL-15 to maintain the survival of NK cells
.
The CAR-NK cells used in the study underwent a freezing and thawing process, indicating that this allogeneic CAR-NK therapy can be used as a novel "off-the-shelf" cell therapy
.
The research team believes that this CAR-NK therapy is promising for the treatment of pancreatic cancer for two reasons: First, the therapy is based on a precision medicine approach, targeting a specific target for pancreatic cancer patients - PSCA; this is an immunotherapy, Using engineered human natural killer cells, engineered to specifically attack cancer cells
.
In addition, solid tumors such as pancreatic cancer, gastric cancer and prostate cancer also highly express prostate stem cell antigen (PSCA).
Therefore, this CAR-NK cell therapy is also promising for gastric and prostate cancer
.
Michael Caligiuri (left), Yu jianhua (right) The research was led by Prof.
Yu jianhua and Prof.
Michael Caligiuri.
Prof.
Yu is the founding director of the NK Cell Biology Research Program at the T-Cell Immunotherapy Center of the City of Hope National Medical Center.
Many important breakthroughs have been made in the fields of biology, CAR-NK, CAR-T, oncolytic virus, and double antibody
.
Professor Michael Caligiuri is the Dean of the City of Hope National Medical Center, the former President of the American Cancer Society (AACR), and a world-renowned medical scientist.
He was elected to the National Academy of Medicine for his breakthrough discoveries in the field of NK cells.
- NK cell therapy has paved the way into the clinic, with more than 1,000 cancer patients currently receiving NK cell therapy designed or co-designed by Michael Caligiuri
.
CytoImmune Therapeutics is developing an NK cell therapy platform designed to overcome the limitations of current engineered NK cell therapies
.
Obtain a large number of NK cells from umbilical cord blood, then add CAR to efficiently identify specific tumor targets, and increase the persistence of CAR-NK cells in vivo by knocking in secreted IL-15
.
More importantly, this engineered CAR-NK can be frozen, stored, and transported without affecting the therapeutic effect, thus enabling "off-the-shelf" cell therapy, which greatly reduces the cost of cell therapy
.
CytoImmune Therapeutics' technology comes from Professor Michael Caligiuri and Professor Yu jianhua, who are also co-founders of the company
.
Reference: https:// https:// /20220118005366/en/ "Bioworld" recently launched the "NK cell therapy" column, which interprets and introduces the latest research progress and reviews of NK cell therapy every week, as well as reports and interviews of related startups
.
We have also established a professional exchange group for NK cell therapy, long press the QR code below, add the editor-in-chief WeChat, and note the unit-research direction/position-name
.
Open reprint welcome to forward to Moments and WeChat groups
